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ACTN1 Mutations Cause Congenital Macrothrombocytopenia
Shinji Kunishima,1,* Yusuke Okuno,2,3 Kenichi Yoshida,2 Yuichi Shiraishi,4 Masashi Sanada,2
Hideki Muramatsu,3 Kenichi Chiba,4 Hiroko Tanaka,4 Koji Miyazaki,5 Michio Sakai,6 Masatoshi Ohtake,7
Ryoji Kobayashi,8 Akihiro Iguchi,9 Gen Niimi,10 Makoto Otsu,11 Yoshiyuki Takahashi,3 Satoru Miyano,4
Hidehiko Saito,12 Seiji Kojima,3 and Seishi Ogawa2
Congenital macrothrombocytopenia (CMTP) is a heterogeneous group of rare platelet disorders characterized by a congenital reduction
of platelet counts and abnormally large platelets, for which CMTP-causing mutations are only found in approximately half the cases.
We herein performedwhole-exome sequencing and targeted Sanger sequencing to identifymutations that cause CMTP, inwhich a domi-
nant mode of transmission had been suspected but for which no known responsible mutations have been documented. In 13 Japanese
CMTP-affected pedigrees, we identified six (46%) affected by ACTN1 variants cosegregating with CMTP. In the entire cohort, ACNT1
variants accounted for 5.5% of the dominant forms of CMTP cases and represented the fourth most common cause in Japanese individ-
uals. Individuals with ACTN1 variants presented with moderate macrothrombocytopenia with anisocytosis but were either asymptom-
atic or had only a modest bleeding tendency. ACTN1 encodes a-actinin-1, a member of the actin-crosslinking protein superfamily that
participates in the organization of the cytoskeleton. In vitro transfection experiments in Chinese hamster ovary cells demonstrated that
altered a-actinin-1 disrupted the normal actin-based cytoskeletal structure. Moreover, transduction of mouse fetal liver-derivedmegakar-
yocytes with disease-associated ACTN1 variants caused a disorganized actin-based cytoskeleton in megakaryocytes, resulting in the
production of abnormally large proplatelet tips, which were reduced in number. Our findings provide an insight into the pathogenesis
of CMTP.Congenital thrombocytopenia is a highly heterogeneous
group of inherited disorders showing low platelet counts.
A subgroup of these disorders is distinguished morpholog-
ically by the production of abnormally large platelets and
is thus referred to as congenital macrothrombocytopenia
(CMTP).1–3 The clinical presentations of CMTP-affected
individuals vary considerably and range from no symp-
toms to a severe bleeding tendency. Thus far, CMTP-
causing mutations have been reported in more than 12
genes.1–3 Among these, the most common is MYH9
(MIM 160775), which is responsible for autosomal-domi-
nant MYH9 disorders or MYH9-related disease (MIM
153650, 153640, 600208, 155100, and 605249)4,5
The second most common are GP1BA (MIM 606672),
GP1BB (MIM 138720), and GP9 (MIM 173515), which
are responsible for autosomal-dominant (heterozygous)
and -recessive (homozygous) Bernard-Soulier syndrome
(MIM 231200).6,7 Less frequent mutations have been
reported in FLI1 (MIM 193067),8 FLNA (MIM 300017),9
GATA1 (MIM 305371),10 ITGA2B/ITGB3 (MIM 607759
and 173470),11,12 NBEAL2 (MIM 614169),13–15 TUBB1
(MIM 612901),16 and VWF (MIM 613160).17 However,
even this array of mutations only accounts for approxi-
mately half the CMTP cases; in the remaining half,
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inappropriate treatments.1–3
To identify mutations that cause CMTP, we first per-
formed whole-exome sequencing of genomic DNA from
11 affected and 10 unaffected individuals from six Japa-
nese CMTP-affected families (Figure 1A) in which a domi-
nant mode of transmission had been suspected but in
which no relevant mutations in the previously reported
genes had been identified (Figure S1, available online).
The candidate mutations found in the exome sequencing
were further examined for germline mutations in addi-
tional CMTP-affected pedigrees and/or individuals by
high-throughput sequencing of PCR products from pooled
DNA and subsequent validation by Sanger sequencing
(Figure 1B). Written informed consent was obtained from
all individuals in accordance with the Declaration of Hel-
sinki. This study was approved by the institutional review
boards of National Hospital Organization Nagoya Medical
Center, The University of Tokyo, and Nagoya University.
For exome sequencing, genomic DNA from each
member of the six pedigrees was enriched for protein-
coding sequences with a SureSelect Human All Exon V3
kit (Agilent Technologies, Santa Clara, CA, USA). This
was followed by massively parallel sequencing with the
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Figure 1. A Flow Diagram of the
Genomic Analysis
(A) Detection of the candidate germline
variants through Genomon-exome.18
(B) Screening ofACTN1 variantswithhigh-
throughput sequencing of pooled DNA.18(Illumina, San Diego, CA, USA). Candidate germline vari-
ants were detected through our in-house pipeline for
exome-sequencing analysis with minor modifications for
the detection of germline variants (Figure 1A).18 The ob-
tained sequences were aligned to the UCSC Genome
Browser hg19 with the Burrows-Wheeler Aligner.19 After
removal of duplicate artifacts caused by PCR, the variants
with an allele frequency > 0.25 were called. With a mean
coverage of 1173 (743–1763), more than 92% of the 50
Mb target sequences were analyzed by greater than ten
independent reads (Figure S2). In total, we identified
3,601 nucleotide variants that had not been registered in
either the in-house SNP database or dbSNP131, and 360
of these cosegregated with macrothrombocytopenia in
the corresponding families. The statistical analysis of the
cosegregating variants indicated that only ACTN1 (MIM
102575, RefSeq accession number NM_001102.3), which
encodes a-actinin-1 (ACTN1), was found to be significantly
mutated in our cohort (Table S1), for which variants
c.313G>A (p.Val105Ile), c.94C>A (p.Gln32Lys), and
c.2255G>A (p.Arg752Gln) were confirmed in pedigrees
exome-1, exome-2, and exome-3, respectively (Figures 2A
and 2B and Table 1). Sanger sequencing in the other seven
dominant CMTP-affected pedigrees revealed an additional
three variants, c.137G>A (p.Arg46Gln), c.2212C>T
(p.Arg738Trp), and c.673G>A (p.Glu225Lys), which also
cosegregated with macrothrombocytopenia within the
individual pedigrees (Figures 2A and 2B and Table 1).
Combined, cosegregating ACTN1 variants were found in
6 (46%)outof 13CMTP-affectedpedigreeswith adominant
mode of transmission (p ¼ 1.67 3 106 compared to
controls by a two-tailed Fisher’s exact test). No ACTN1 vari-
ants were detected among the 120 control individuals or
39 cases of sporadic CMTP, for which the mode of trans-
mission had been unknown; the only exception was
c.589C>T (p.Arg197Trp), which was found in a control
individual who had a normal platelet count and size (Fig-
ure 1B and Figure S3). The multiple-sequence alignment432 The American Journal of Human Genetics 92, 431–438, March 7, 2013indicated that all missense variants
had highly conserved amino acid
residues (Figure S4). Furthermore,
different function-prediction pro-
grams suggested deleterious effects of
these variants (Table S2). These results
strongly suggest that these ACTN1
variants represent autosomal-domi-
nant CMTP-causing mutations.
Individuals with mutant ACTN1
alleles had approximately half thenormal platelet counts and a 30% increase in platelet size
(Table 1 and Figure 3A). The platelet size in ACTN1-
mutated individuals was smaller than that in individuals
with a MYH9 disorder or homozygous Bernard-Soulier
syndrome but was similar to that in individuals with
heterozygous Bernard-Soulier syndrome or GPIIb/IIIa-
associated macrothrombocytopenia (data not shown).
Electron microscopy showed no other abnormalities
(Figure 3B). The macrothrombocytopenia was accompa-
nied by anisocytosis. Bleeding diathesis was absent or
mild if present: only two individuals (15%) experienced
occasional epistaxis, and the bleeding time was within
the normal limit (Table 1). In addition, no apparent
in vitro defects in platelet functions, including normal
platelet aggregation (Table 1), clot retraction, and platelet
spreading on glass surfaces, were noted in ACTN1-mutated
individuals (Figure S5). Flow cytometry showed increased
expression of platelet GPIb/IX and GPIIb/IIIa, which
were thought to reflect the increased platelet size (data
not shown).
The affected protein, a-actinin, is a member of the actin-
crosslinking protein superfamily that participates in the
organization of the cytoskeleton.20,21 Among the four
known isoforms of a-actinin, ACTN2 (MIM 102573) and
ACTN3 (MIM 102574) are relatively specific to muscle
cells, whereas ACTN1 and ACTN4 (MIM 604638) are
widely expressed in nonmuscle cells. Platelets and mega-
karyocytes mainly express ACTN1 and, to a lesser extent,
ACTN4.22 The a-actinins exist as antiparallel dimers with
an actin-binding domain (ABD) at the N terminus and
cross-link actin filaments in bundles (Figure 2C). All of
the identified ACTN1 mutations reside within the func-
tional domain (the ABD and the C-terminal calmodulin-
like domain), but not within the spacer spectrin repeats
(Figure 2D). Therefore, ACTN1 variants that have differ-
ences in their structure and/or function might exert
a dominant-negative effect, causing disorganization of
actin filaments, although the localization and expression
Exome-1
p.Val105Ile
p.Val105Ile
WT
Exome-2
p.Gln32Lys
p.Gln32Lys
p.Gln32Lys WT
WT
Exome-3
p.Arg752Gln
p.Arg752Gln
WT
WT
Sanger-1
p.Arg46Glnp.Arg46Gln
p.Arg46Gln N/A
Sanger-2
p.Arg738TrpN/A
N/A N/A
N/A N/A
Sanger-3
p.Glu225LysN/A
N/A p.Glu225Lys
Variant
WT
c.94C>A 
(p.Gln32Lys)
c.137G>A 
(p.Arg46Gln)
c.313G>A 
(p.Val105Ile)
c.673G>A 
(p.Glu225Lys)
c.2212C>T 
(p.Arg738Trp)
c.2255G>A 
(p.Arg752Gln)
5' 3' 
p.Gln32Lys 
p.Val105Ile
p.Arg752Gln p.Arg46Gln
p.Arg738Trp
p.Glu225Lys
2 7Exon 1 183
A
B
-Actinin
Actin filament
C D
ABD
CH2CH1
CaMR1 R2 R3 R4
ABD
CH2CH1
CaM R4 R3 R2 R1
Figure 2. Segregation of ACTN1 Variants, the ACTN1 Structure, a-Actinin-Actin Interaction, and the a-Actinin Domain Structure
(A) The pedigrees for the six families affected by ACTN1 variants are shown together with the Sanger-sequencing electropherograms.
Filled symbols represent individuals affected by macrothrombocytopenia. The identified ACTN1 variants are shown below the symbols.
The arrows indicate nucleotide changes. The following abbreviations are used: WT, wild-type; and NA, not available.
(B) Genomic organization of ACTN1, variants in which are identified in individuals with CMTP.
(C) a-actinin cross-links actin filaments into actin-filament bundles.
(D) a-actinin consists of an N-terminal actin-binding domain (ABD), composed of two calponin homology domains (CHD), four spectrin
repeats (R1–R4), and a C-terminal calmodulin-like domain (CaM). Two molecules form an antiparallel dimer. The arrows indicate the
positions of the identified ACTN1 variants.of ACTN1 in the individuals’ platelets was similar to that in
controls (Figure S6). However, ACTN4missense mutations,
which are implicated in familial focal segmental
glomerulosclerosis (MIM 603278), promote the aggrega-
tion of a-actinin-4 molecules and abrogate the integrity
of actin filaments in transfected cells.23,24
We therefore first evaluated the effects of mutant ACTN1
on the organization of actin filaments by expressing each
of the seven identified ACTN1 variants in Chinese hamster
ovary (CHO) cells. A full-length ACTN1 sequence was
amplified from normal platelet cDNA and constructed
into mammalian expression vector pcDNA3.1 (Invitrogen,
San Diego, CA, USA) with a 50 Myc tag sequence. Six altered
ACTN1 constructs (p.Gln32Lys, p.Arg46Gln, p.Val105Ile,
p.Glu225Lys, p.Arg738Trp, and p.Arg752Gln) identified
exclusively in the affected individuals and one construct
(p.Arg197Trp) also identified in a control individual were
prepared. Plasmid DNA was transfected into CHO cells
with the PolyFect transfection reagent (QIAGEN, Hilden,
Germany). Twenty-four hours after transfection, theThe AmeACTN1-transduced cells were replated on fibronectin
(10 mg/ml)-coated coverslips for an immunofluorescence
analysis.16 As shown in Figure 4, cells transduced with
wild-type ACTN1 showed well-organized, fine actin-fila-
ment networks, where ACTN1 colocalized in a large part
onto the actin filaments, whereas unbound ACTN1 was
finely distributed within the cytoplasm. In contrast, except
for the p.Arg197Trp variant found in a control individual,
all ACTN1 variants caused varying degrees of disorganiza-
tion of the actin filaments in variant-transduced cells, in
which ACTN1 colocalized with less fine, shortened actin
filaments and in which unbound ACTN1 was coarsely
distributed within the cytoplasm (some cells showed punc-
tuated or condensed staining).
We further investigated whether altered ACTN1 also
causes disorganization of the actin cytoskeleton in mega-
karyocytes by expressing wild-type and altered ACTN1
(p.Gln32Lys and p.Val105Ile) in primary mouse fetal
liver-derived megakaryocytes by retrovirus-mediated gene
transfer.11 We subcloned wild-type and mutant ACTN1rican Journal of Human Genetics 92, 431–438, March 7, 2013 433
Table 1. ACTN1 Mutations and Platelet Characteristics
Family
DNA
Mutation
Protein
Alteration
Platelet
Count
( 3 109/l)
Platelet
Size (mm)a
Bleeding
Tendency
Duke
Bleeding
Time (min)
Platelet
Aggregation
ADP (%) Initial Diagnosis
Exome-1 mother c.313G>A p.Val105Ile 80 3.75 1.1 none - - -
proband c.313G>A p.Val105Ile 91 3.85 1.4 none - - immune thrombocytopenia
Exome-2 father c.94C>A p.Gln32Lys 113 2.75 0.9 none - - congenital thrombocytopenia
proband c.94C>A p.Gln32Lys 54 3.15 1.1 none 4.5 34 (2 mM) congenital thrombocytopenia
brother c.94C>A p.Gln32Lys 124 2.95 0.9 epistaxis - - congenital thrombocytopenia
Exome-3 mother c.2255G>A p.Arg752Gln 100 ND none - - immune thrombocytopenia
proband c.2255G>A p.Arg752Gln 77 2.95 0.6 none - 49 (2 mM) CMTP
Sanger-1 father c.137G>A p.Arg46Gln 131 4.25 1.3 none 1 76 (2 mM) -
proband c.137G>A p.Arg46Gln 120 3.95 1.6 none - 66 (2 mM) CMTP
sister c.137G>A p.Arg46Gln 97 3.65 1.4 none - 74 (2 mM) CMTP
Sanger-2 proband c.2212C>T p.Arg738Trp 77 3.75 1.5 none 2 - CMTP
Sanger-3 proband c.673G>A p.Glu225Lys 80 3.05 0.9 epistaxis - 59 (2.5 mM) CMTP
mother c.673G>A p.Glu225Lys 132 2.85 0.8 none - - -
Mean 5 SD - - - 98.1 5 23.2 3.45 0.5 - - - -
The following abbreviations are used: ND, not done; and CMTP, congenital macrothrombocytopenia.
aDetermined by a microscopic observation of 200 platelets on a stained peripheral-blood smear. Control size ¼ 2.5 5 0.3 mm (n ¼ 31).cDNAs into retroviral vector pGCDNsamIRES/EGFP with
a 50 Myc tag sequence and transfected them into 293 gpg
packaging cells to obtain viral stocks.25 We used the vesic-
ular stomatitis virus G protein to pseudotype the envelope
of the virus. Mouse fetal liver cells harvested from embry-
onic day 13.5 embryos were transduced with either vehicle
vector or pGCDNsamIRES/EGFP ACTN1 and were culturedControl Exome-1 proband
Control Exome-3 proband
A
B
3.8 ± 1.4 µm2.5 ± 0.6 µm
Sanger
Sanger
TAAB, Berkshire, UK). Ultrathin sections (0.1 mm) were doubly sta
observed with a transmission electron microscope (H-7650, Hitach
magnification is 31,500. The scale bar represents 2 mm.
434 The American Journal of Human Genetics 92, 431–438, March 7with 40 ng/ml recombinant mouse thrombopoietin. The
Experimental Animal Committee of Nagoya Medical
Center approved the animal studies.
On posttransduction day 3, large megakaryocytes
were enriched with a 1.5/3% BSA gradient and were then
incubated on fibrinogen-coated coverslips for 45 min
in the presence of 100 nM phorbol myristate acetate.263.0 ± 0.9 µm
-3 proband
-3 proband
Figure 3. The Platelet Morphology
(A) Peripheral-blood smears were stained
with May-Gru¨nwald Giemsa for a normal
control, the exome-1 proband, and the
Sanger-3 proband. The affected individ-
uals showed macrothrombocytopenia
accompanied by anisocytosis. The number
in each panel shows the mean platelet size
(n ¼ 200). Images were obtained with a
BX50 microscope with a 1003/1.35
numeric aperture oil objective (Olympus,
Tokyo, Japan). Images of the slides were
acquired with a DP70 digital camera and
DPmanager software (Olympus). The orig-
inal magnification is 31,000.
(B) The ultrastructure of platelets from
a normal control, the exome-3 proband,
and the Sanger-3 proband. Platelet-rich
plasma was prepared from acid-citrate-
dextrose-citrated whole blood that was
fixed in 2% glutaraldehyde and postfixed
in 1% osmium tetroxide. The samples
were then dehydrated in a graded ethanol
series and n-butyl glycidyl ether and
embedded in an epoxy resin (Epon 812;
ined with 2% uranyl acetate and 1% lead citrate and were then
i, Tokyo, Japan) at an accelerating voltage of 80 kV. The original
, 2013
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Figure 4. The Subcellular Localization of Altered ACTN1 in CHO Cells
CHO cells were transiently transfected withMyc-tagged wild-type or mutant ACTN1 cDNAs. After the cells were replated on fibronectin-
coated coverslips, they were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100. They were then stained with
Myc-tagged antibody (Invitrogen), followed by Alexa-488-labeled goat anti-mouse IgG, Alexa-555-conjugated phalloidin (Invitrogen),
and DAPI. Images were obtained with a BX50 fluorescence microscope with a 403/1.00 numerical aperture oil objective lens. The cells
shown are representative of eight independent experiments.
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Figure 5. Abnormal Proplatelet Formation in Megakaryocytes Transduced with Altered ACTN1
(A) The organization of the actin filaments in megakaryocytes adhered to fibrinogen. The scale bar represents 50 mm.
(B) The percentage of megakaryocytes extending proplatelets was evaluated under an IX71 fluorescence microscope with a 203/0.40
objective lens (Olympus) 2–4 days after infection. For each specimen, at least 100 megakaryocytes were evaluated.
(C) The number of proplatelet tips per megakaryocyte was decreased in megakaryocytes transduced with mutant ACTN1.
(D) The size of proplatelet tips was increased in megakaryocytes transduced with altered ACTN1.
(E) Representative megakaryocytes extending proplatelets 3 days after infection. Note that the size of the proplatelet tips was variable in
the megakaryocytes transduced with altered ACTN1 (arrows indicate large tips, and arrowheads indicate small tips). The scale bar repre-
sents 50 mm.
(F) The proplatelet morphology and a-tubulin localization of EGFP-positive megakaryocytes. Infection day 3 cultures were cytospun
onto glass slides. Cells were then fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, and stained with GFP
antibody (D153-3; Medical & Biological Laboratories, Nagoya, Japan) and a-tubulin antibody (RB-9281; Lab Vision, Fremont, CA),
followed by Alexa-488-labeled goat anti-rat IgG and Alexa-555-labeled goat anti-rabbit IgG (Invitrogen). Images were obtained with
a BX50microscope with a 1003/1.35 numeric aperture oil objective lens (Olympus). The size of the proplatelet tips was variable inmega-
karyocytes transduced with altered ACTN1 (arrows indicate large tips, and arrowheads indicate small tips). The scale bar represents
20 mm. Representative images from four independent experiments are shown.Cells were fixed, permeabilized, and stained with phalloi-
din, and then green-fluorescent-protein (GFP)-positive
megakaryocytes were observed under a fluorescencemicro-
scope. Megakaryocytes adhere to fibrinogen-coated sur-
faces through the integrin aIIbb3 receptor and undergo
cytoskeletal reorganization. Cells transduced with wild-
type ACTN1 reorganized the actin cytoskeleton with the
development of organized actin filaments, which were
circumferential and parallel to the cell periphery. However,
the circumferential actin-filament network was less orga-
nized in the megakaryocytes transduced with altered
ACTN1 than in control cells (Figure 5A). These findings
indicate that CMTP-associated ACTN1 mutations domi-
nantly affect the actin-filament assembly and might result
in abnormal cytoskeletal organization.436 The American Journal of Human Genetics 92, 431–438, March 7According to the current model of platelet production,
differentiated megakaryocytes extend long, branching
multiple microtubule-based protrusions, called proplate-
lets, into the bone-marrow sinusoids, which are composed
of platelet-sized swellings, or tips, in tandem arrays that are
mutually connected by thin cytoplasmic bridges.27 Propla-
telets are then released into the blood stream, where
terminal production of mature platelets takes place
through several intermediate forms.28 The proplatelet
formation and their release from megakaryocytes, as well
as the subsequent production of mature platelets in the
periphery, are spatially and temporally regulated by
dynamic reorganization of the cytoskeletons and signal
transduction.29 Several lines of evidence suggest that
macrothrombocytopenias are caused by defects in the, 2013
regulation of terminal platelet production.30 In fact, most
of the previously reported defects responsible for CMTP
affect genes involved in the signaling pathways and/or
components of the cytoskeleton;30 these defects include
mutations in integrin aIIbb3 (ITGA2B/ITGB3),11,12 GPIb/
IX (GP1BA, GP1BB, and GP9),5,6 nonmuscle myosin heavy
chain IIA (MYH9),4,5 actin-binding protein filamin A
(FLNA),9 and b1-tubulin (TUBB1).16
To further explore the effects of mutant ACTN1 on
proplatelet formation, after transducing ACTN1 variants
into primary mouse fetal liver-derived megakaryocytes,
we monitored proplatelet formation in enhanced-GFP
(EGFP)-positive megakaryocytes in suspension by inverted
fluorescence microscopy. The cultures were then spread
onto glass slides and subsequently analyzed by immuno-
fluorescence staining. During the 4 day culture period,
the proportion of proplatelet-formation-positive megakar-
yocytes was not different among wild-type-, p.Gln32Lys-,
and p.Val105Ile-transduced megakaryocytes, suggesting
that ACTN1 variants do not accelerate or inhibit the
rate of proplatelet formation and/or platelet production
(Figure 5B). However, the number of proplatelet tips
tended to be decreased, and the size of the tips increased
in the megakaryocytes transduced with both altered forms
of ACTN1 (Figures 5C and 5D).
During proplatelet formation, microtubules function to
propel proplatelet elongation, and the actin cytoskeleton
plays a critical role in bending and bifurcating the propla-
telet shaft to increase the number of proplatelet tips. Cyto-
chalasin-mediated inhibition of actin polymerization has
been shown to interfere with proplatelet branching.27
Moreover, mouse models for null alleles of actin-modu-
lating genes, such as cofilin-1 (Cfl1), and a hypomorphic
allele of WD repeat domain 1 (Wdr1) exhibit macrothrom-
bocytopenia, indicating that dynamic changes in the actin
cytoskeleton are required for normal platelet produc-
tion.31,32 Because ACTN1 plays a pivotal role in crosslink-
ing actin filaments,20,21 defective ACTN1 variants could
cause deregulated actin-filament organization, as shown
in CHO cells and cultured megakaryocytes (Figures 4 and
5A). Furthermore, we found that the platelet tips in wild-
type-ACTN1-transduced megakaryocytes were uniform in
size, whereas they were heterogeneous in the variant-trans-
duced cells (Figures 5E and 5F). These results are consistent
with the thrombocytopenia and increased platelet size
(macrothrombocytopenia) accompanied by anisocytosis
in the affected individuals, demonstrating that abnormal
ACTN1 affects proplatelet formation.
In addition to playing a role in actin bundling, a-acti-
nins have been shown to interact with a number of other
cytoskeletal and receptor proteins.20,21 In platelets,
ACTN1 binds to b integrins and can mediate their
signaling.33 Thus, similar to the activating mutations in IT-
GA2B/ITGB3,11,12 ACTN1 mutations could also affect pro-
platelet formation through abnormal integrin signaling.
In summary, we identified ACTN1 mutations that cause
autosomal-dominant CMTP. In our cohort, ACNT1 vari-The Ameants accounted for 5.5% of the dominant forms of CMTP
cases, representing the fourth most common cause of
Japanese CMTP. Our finding clearly demonstrates the
effectiveness of whole-exome sequencing of CMTP-
affected pedigrees for clarifying their genetic basis,
although the limitation of the available pedigree samples
for exome sequencing prevented further identification of
the causative genes for the remaining families. Such
studies also facilitate the differential diagnosis of congen-
ital macrothrombocytopenia and can provide important
information about the mechanisms of platelet production.Supplemental Data
Supplemental Data include six figures and two tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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